• Price (USD)143.38
  • Today's Change5.67 / 4.12%
  • Shares traded2.00k
  • 1 Year change-9.25%
  • Beta1.6707
Data delayed at least 15 minutes, as of May 19 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

  • Revenue in USD (TTM)22.60bn
  • Net income in USD14.64bn
  • Incorporated2016
  • Employees2.70k
  • Location
    Moderna Inc200 Technology SqCambridge 02139-3578United StatesUSA
  • Phone+1 (617) 714-6500
  • Fax+1 (617) 583-1998
  • Websitehttps://www.modernatx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
AmerisourceBergen Corp.229.67bn1.73bn31.65bn38.00k18.4657.5013.140.13788.198.191,089.892.634.4015.5713.166,043,852.003.330.163412.410.66143.522.890.75610.03650.558313.780.8769473.0912.697.82145.181.52-1.165.29
DuPont de Nemours Inc15.95bn1.43bn32.69bn28.00k23.531.2511.262.052.732.9930.5951.470.34234.396.46569,678.603.21-0.22273.68-0.28934.7931.609.37-1.612.385.440.2918--16.15-19.13172.14-15.09-25.20-26.30
Iqvia Holdings Inc14.03bn1.08bn37.34bn79.00k35.576.3116.402.665.555.5572.0931.270.5677--5.64177,632.904.371.775.532.1433.9934.307.703.64--4.430.6810.0022.1415.28246.2468.0831.30--
McKesson Corporation263.97bn1.12bn46.61bn58.00k44.80--22.720.17667.167.121,703.28-15.674.1113.2113.984,551,138.002.01-0.75487.65-2.385.035.240.4895-0.20140.56840.831.44--10.805.86124.66-26.44-0.97999.71
Moderna Inc22.60bn14.64bn54.78bn2.70k4.053.233.672.4234.0134.0152.5042.691.122.837.088,370,371.0072.6441.17129.4066.7884.77--64.7752.351.56--0.04510.002,199.12179.441,733.33--53.67--
Vertex Pharmaceuticals Incorporated7.95bn2.45bn64.54bn3.90k26.595.9124.988.129.499.4930.7042.680.60283.007.002,037,845.0018.5918.0122.0421.8787.9587.7730.8429.174.6047.320.04350.0022.0634.79-13.63--32.96--
Regeneron Pharmaceuticals Inc16.51bn7.93bn72.41bn10.37k9.343.628.804.3970.5670.56146.35181.860.74831.623.661,592,216.0035.9625.6441.8729.9984.6588.5148.0639.114.27360.500.1194--89.1427.02129.8655.241.52--
Zoetis Inc7.89bn2.07bn74.76bn12.10k36.4516.0729.639.474.364.3616.599.890.57071.236.72652,148.8014.9713.7918.3616.0470.7668.7526.2323.941.5811.500.585422.5316.499.7324.3619.9317.1720.72
Gilead Sciences, Inc.27.47bn4.52bn79.30bn14.40k17.663.9812.032.893.583.5821.7815.880.42084.097.121,907,778.006.888.358.0010.0275.7479.5616.3522.221.307.420.568258.7610.60-2.124,960.98-14.34-4.999.07
Data as of May 19 2022. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD

Institutional shareholders

33.11%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 31 Mar 202245.63m11.32%
The Vanguard Group, Inc.as of 31 Mar 202225.61m6.36%
BlackRock Fund Advisorsas of 31 Mar 202219.89m4.94%
SSgA Funds Management, Inc.as of 31 Dec 202114.86m3.69%
Geode Capital Management LLCas of 31 Mar 20226.44m1.60%
Th�l�me Partners LLPas of 31 Mar 20226.34m1.57%
Coatue Management LLCas of 31 Dec 20214.29m1.06%
Renaissance Technologies LLCas of 31 Mar 20223.82m0.95%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 20223.50m0.87%
Norges Bank Investment Managementas of 31 Dec 20213.04m0.76%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.